The article reports on the launch of a biological compound Alzumab (itolizumab), an immunized monoclonal antibody, for chronic plaque psoriasis in the Indian market by biotech company Biocon. The topics discussed include the drugs targeting of CD6 proteins found on T-cells, price of Alzumab and efficacy and safety data of the drug.